CRVS
NASDAQCorvus Pharmaceuticals Inc.
News · 26 weeks38+100%
2026-03-012026-08-23
Mix1390d
- Insider5(38%)
- SEC Filings4(31%)
- Other2(15%)
- Earnings2(15%)
Latest news
25 items- SECSEC Form SCHEDULE 13G filed by Corvus Pharmaceuticals Inc.SCHEDULE 13G - Corvus Pharmaceuticals, Inc. (0001626971) (Subject)
- SECSEC Form 10-Q filed by Corvus Pharmaceuticals Inc.10-Q - Corvus Pharmaceuticals, Inc. (0001626971) (Filer)
- SECCorvus Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Corvus Pharmaceuticals, Inc. (0001626971) (Filer)
- PRCorvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial ResultsEnrollment in soquelitinib registrational Phase 3 relapsed/refractory peripheral T-cell lymphoma (PTCL) and Phase 2 atopic dermatitis trials on track Soquelitinib’s potential in atopic dermatitis and broader immunology and inflammation indications supported by Phase 1 clinical, immunologic and biomarker data presented at the Society for Investigative Dermatology (SID) annual meeting Cash, cash equivalents and marketable securities of $215.2 million at June 30, 2026, providing runway into 2Q28 Conference call and webcast today at 4:30 pm ET / 1:30 pm PT SOUTH SAN FRANCISCO, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmace
- PRCorvus Pharmaceuticals to Provide Business Update and Second Quarter 2026 Financial Results on August 6, 2026SOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on August 6, 2026 at 4:30 pm ET (1:30 pm PT) to provide a business update and report second quarter 2026 financial results. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus’ website for 90 da
- SECCorvus Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update8-K - Corvus Pharmaceuticals, Inc. (0001626971) (Filer)
- INSIDERDirector Moore David Scott bought $250,236 worth of shares (21,700 units at $11.53) (SEC Form 4)4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)
- INSIDERSEC Form 4 filed by Director Clark Ian T4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)
- INSIDERSEC Form 4 filed by Director Grais Linda4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)
- INSIDERSEC Form 4 filed by Director Thompson Peter A.4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)
- INSIDERSEC Form 4 filed by Director Van Den Broek Richard4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)
- SECCorvus Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Corvus Pharmaceuticals, Inc. (0001626971) (Filer)
- PRCorvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in ChinaSOUTH SAN FRANCISCO, Calif., June 09, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that it has participated in a new $13.5 million financing for Angel Pharmaceuticals Ltd. (Angel Pharma), the Company's collaboration partner in China. Corvus co-founded Angel Pharma in 2020 to enable the clinical development and commercialization of its pipeline in China as well as the development of other novel drugs. Corvus is Angel Pharma's largest shareholder and is investing $5 million in the current financing. The funding is anticipated to support Angel Pharma's ongoing Phase 1b/2 trial of soquelitinib for atopic derma
- INSIDERPresident and CEO Miller Richard A Md bought $83,453 worth of shares (6,932 units at $12.04) (SEC Form 4)4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)
- PRCorvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare ConferenceSOUTH SAN FRANCISCO, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and present a corporate overview at the 2026 Jefferies Global Healthcare Conference, to be held in New York, NY, and the Goldman Sachs 47th Annual Global Healthcare Conference, to be held in Miami, FL. The Jefferies presentation is scheduled for Wednesday, June 3, 2026 at 3:45 PM ET, and the Goldman Sachs presentation is scheduled for Monday, June 8, 2026 at 11:20 AM ET. A webcast of the presentations will be available live and for 90 days fol
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Corvus Pharmaceuticals Inc.SCHEDULE 13G/A - Corvus Pharmaceuticals, Inc. (0001626971) (Subject)
- SECCorvus Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Corvus Pharmaceuticals, Inc. (0001626971) (Filer)
- PRCorvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual MeetingNew immunologic and biomarker data supports the potential of ITK inhibition with soquelitinib to increase persistent Treg cells and influence multiple inflammatory pathways. Data supports potential for soquelitinib to rebalance the immune system and produce drug-free remissions following discontinuation of therapy Immunologic markers consistent with soquelitinib's novel mechanism of action and clinical results SID data included in late-breaking oral presentation; company to review data at investor and analyst meeting today at 1:30 pm ET (12:30 pm CT) SOUTH SAN FRANCISCO, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceut
- SECSEC Form S-8 filed by Corvus Pharmaceuticals Inc.S-8 - Corvus Pharmaceuticals, Inc. (0001626971) (Filer)
- SECSEC Form 10-Q filed by Corvus Pharmaceuticals Inc.10-Q - Corvus Pharmaceuticals, Inc. (0001626971) (Filer)
- SECCorvus Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Corvus Pharmaceuticals, Inc. (0001626971) (Filer)
- PRCorvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial ResultsSoquelitinib clinical development for atopic dermatitis advancing with Phase 1 cohort 4 positive data and initiation of Phase 2 trial during the quarter New immunologic and biomarker data supporting the potential for drug-free remissions with soquelitinib to be presented at Society for Investigative Dermatology (SID) annual meeting Company hosting investor and analyst meeting to review SID data on May 14, 2026 at 1:30 pm ET (12:30 pm CT) SOUTH SAN FRANCISCO, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the first quarter ended March 31, 2
- INSIDERSEC Form 4 filed by Director Chan Andrew C.4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)
- INSIDERSEC Form 3 filed by new insider Chan Andrew C.3 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)
- SECSEC Form DEF 14A filed by Corvus Pharmaceuticals Inc.DEF 14A - Corvus Pharmaceuticals, Inc. (0001626971) (Filer)
CRVS FAQ
7 questionsWhat does Corvus Pharmaceuticals Inc. do?
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-006, an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial that inhibits the production of adenosine and activate various immune cells, as Phase III clinical trial of CPI-006 for COVID-19. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas; and Ciforadenant (CPI-444), an oral, small...Where does CRVS stock trade?
Corvus Pharmaceuticals Inc. (CRVS) is listed on NASDAQ.What sector and industry is CRVS in?
Corvus Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Corvus Pharmaceuticals Inc. go public?
Corvus Pharmaceuticals Inc. (CRVS) completed its IPO in 2016.What are analysts saying about CRVS?
Corvus Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Goldman: Buy with a $4000.00 price target on 2026-04-17.What companies are similar to CRVS?
Notable peers in the same industry include RCUS (Arcus Biosciences Inc.), ITOS (iTeos Therapeutics Inc.), CANF (Can-Fite Biopharma Ltd). Compare CRVS side-by-side with any of them on Quantisnow.How can I track CRVS on Quantisnow?
Quantisnow aggregates Corvus Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CRVS to receive live email and push alerts on every new disclosure.